<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203172/" ref="ordinalpos=3258&amp;ncbi_uid=3321084&amp;link_uid=PMC3203172" image-link="/pmc/articles/PMC3203172/figure/pone-0027053-g004/" class="imagepopup">Figure 4. PI3K <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> activation protected cells from apoptosis induced by combination treatment of LY294002 and tamoxifen..  From: Sensitization of Glioma Cells to Tamoxifen-Induced Apoptosis by Pl3-Kinase Inhibitor through the GSK-3?/?-Catenin <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>. </a></div><br /><div class="p4l_captionBody">U251 cells were treated with 10 µmol/L LY294002 (LY), or/and 5 µmol/L tamoxifen (TAM), or combination of LY and TAM with additional IGF-1 (50 ng/ml) for 12 h, followed by Annexin V-FITC/propidium iodide staining. Columns representing the flow cytometry data presented in left. Data are means ±S.E.M. of values from three independent experiments; FL2-H, propidium iodide; FL1-H, Annexin V.</div></div>